Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMC-376 in KRAS G12C Mutated Advanced Solid Tumors
NCT06244771Phase 2Recruiting
- Sponsor
- Frontier Medicines
- Start
- Feb 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of FMC-376 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Frontier Medicines. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events at 24 months and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
FMC-376
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06244771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06244771.